drugset / Trial / NCT02204683

Pharmacokinetic Study of Intravitreal Aflibercept Injection in Eyes With Wet Age-related Macular Degeneration

NCT02204683

Non-randomizedSingle-groupOpen-labelOther

Summary

The main goal is to study way that aflibercept injection behaves in the eye and in the body of patients with wet macular degeneration, in patients who have had previous vitreous removal surgery.

Timeline

Start
2014-09-05
Primary completion
2016-12-14
Completion
2016-12-14

Drugs

EvaluationDrugModalityDoseRoute
Subject Aflibercept Protein / enzyme biologic 2 mg Intravitreal